latest news releases from the newsroom
Orbit International Corp.
Orbit International's Electronics Group Receives Critical Design Awards Valued in Excess of $940,000
HAUPPAUGE, N.Y., April 22, 2009 (GLOBE NEWSWIRE) -- Orbit International Corp. (Nasdaq:ORBT), a defense electronics manufacturer, systems integrator and software solution provider, today announced that its Electronics Group, Tulip Development Laboratory, Inc, ("Tulip") has received two new prototype design and qualification contracts totaling approximately $940,000. Both orders will be designed, engineered and manufactured in the Company's Quakertown, PA. facility. Deliveries under both of these contracts are expected to commence in the third quarter of 2009 and continue through the fourth quarter of 2009.
Virgin Media Inc.
Virgin Media Notification of First Quarter 2009 Results
LONDON, April 22, 2009 (GLOBE NEWSWIRE) -- Virgin Media (Nasdaq:VMED) will be announcing its First Quarter 2009 results on Tuesday, May 5, 2009 at 8 am UK time, 3 am ET. The company will host a conference call for analysts and investors to discuss these results on May 5, at 1 pm UK time, 8 am ET.
Primoris Services Corporation
Primoris Services Corporation Receives $25 Million Contract From Major California Utility
LAKE FOREST, Calif., April 22, 2009 (GLOBE NEWSWIRE) -- Primoris Services Corporation (Nasdaq:PRIM) (Nasdaq:PRIMU (Nasdaq:PRIMW) ("Primoris" or "Company"), one of the largest specialty contractors and engineering companies in the United States, today announced that its wholly-owned subsidiary, ARB, Inc., has been awarded a contract from a major California utility to replace certain existing copper natural gas services that have been in place for over 50 years with new high-density polyethylene ("HDPE") services. The agreement is expected to generate aggregate revenues to Primoris of at least $25 million for the period March - December 2009.
Immunomedics Reports Preclinical Results of Novel Protein Constructs From Dock-and-Lock
DENVER, April 22, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the results of four preclinical studies involving new antibody-cytokine conjugates and cytokines site-specifically PEGylated using the Company's and its majority-owned subsidiary, IBC Pharmaceuticals, Inc.'s proprietary Dock-and-Lock method (DNL) for protein engineering.